rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACXP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Acurx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceACXP
      Earnings call transcript: Acurx posts q3 2026 loss miss as trial progress lifts shares
      Nov 12Investing.comACXP
      Acurx Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 12BenzingaACXP
      Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
      Nov 12Yahoo FinanceACXP
      Acurx Pharmaceuticals lowers quorum requirement for shareholder meetings
      Oct 29Investing.comACXP
      Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
      Oct 26Yahoo FinanceACXP
      Acurx publishes study on microbiome effects of antibiotic class
      Oct 21Investing.comACXP
      Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
      Oct 21Yahoo FinanceACXP
      Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
      Oct 5Yahoo FinanceACXP
      Acurx enrolls first patient in recurrent C. difficile trial
      Sep 29Investing.comACXP
      Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

      Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo

      Sep 29Yahoo FinanceACXP
      New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
      Sep 19Yahoo FinanceACXPLTRN
      Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
      Sep 18BenzingaACXP
      Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

      Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a late clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific poster entitled: Comparative In Vitro Killing Kinetics of Ibezapolstat and Comparator Antibiotics in Clostridioides difficile and Vancomycin-resistant Enterococcus Co-Cultures was presented at the 9th International C. difficile Symposium held in Bled, Slovenia from September 8-10, 2026. The

      Sep 14Yahoo FinanceACXP

      This is the newest page. Registered accounts read further back.